Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimarafenib + Panitumumab in Advanced RAS Mutant CRC and PDAC
NCT06194877Phase 1Terminated
- Sponsor
- MapKure, LLC
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of Brimarafenib in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by MapKure, LLC. Primary endpoints: Number of Participants with Serious Adverse Events up to 2 years, Number of Participants with Treatment-emergent Adverse Events up to 2 years and 6 more. Started Apr 2024; status: terminated.
02
Drugs
Brimarafenib
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06194877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194877.